(Bloomberg) -- Jazz Pharmaceuticals Inc. failed to win a U.S. panel’s backing for an experimental fibromyalgia drug that includes a chemical linked to date rape.
The treatment, known as JZP-6, doesn’t provide enough benefits to outweigh risks of abuse and accidental overdose, outside advisers to the Food and Drug Administration said in a 20-2 vote today in Bethesda, Maryland. While the FDA usually follows its advisory panels’ recommendations, it isn’t required to do so.
No comments:
Post a Comment